文献速递肝病消化道肿瘤与早癌

通过克服小鼠肝脏免疫耐受增强程序性死亡配体1抗体对转移性肝癌的治疗效果

Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
PubMed 文献 · Hepatology · 2022-01-23

该研究在小鼠中比较了抗PD-L1抗体对皮下与肝脏同一肿瘤的效果,发现抗PD-L1单药显著抑制皮下肿瘤生长但对转移性肝癌无效;抗PD-L1联合聚肌胞苷酸可强效抑制肝脏肿瘤进展,其机制涉及下调髓源性抑制细胞、上调M1/M2巨噬细胞、CD8/CD4及CD8/调节性T细胞比例,并维持长效细胞毒性T细胞。

要点

  • 抗PD-L1单药显著抑制皮下肿瘤生长,但对转移性肝癌无效。
  • 抗PD-L1联合聚肌胞苷酸强效抑制肝脏肿瘤进展。
  • 联合治疗依赖巨噬细胞和Ⅰ型干扰素信号通路。

核心结论

  • 肝癌对αPD-L1治疗反应差主要归因于独特的肝脏免疫耐受微环境,与肿瘤来源或类型无关。
  • 联合免疫治疗的成功依赖于协调抑制或激活多种固有和适应性免疫细胞活性。

研究设计与样本

  • 研究在小鼠中通过皮下接种MC38结直肠癌细胞生成皮下肿瘤,通过门静脉或脾脏注射结直肠癌细胞生成转移性肝癌。
  • 荷瘤小鼠接受腹腔注射αPD-L1、聚肌胞苷酸或两者联合治疗。

主要发现

  • αPD-L1单药显著抑制皮下肿瘤生长,但对转移性肝癌无效果。
  • αPD-L1联合聚肌胞苷酸强效抑制肝脏肿瘤进展。
  • 联合治疗有效下调髓源性抑制细胞,上调浸润肝脏肿瘤和全肝的M1/M2巨噬细胞、CD8/CD4及CD8/调节性T细胞比例。
  • 联合治疗组肝脏中维持一群长效T-bet+ Eomes- PD-1-细胞毒性T细胞,导致对肿瘤复发的抵抗。
  • 耗竭巨噬细胞或阻断Ⅰ型干扰素信号可消除αPD-L1与聚肌胞苷酸的协同抗肿瘤效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Immunotherapy with programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade has shown low response rates in liver cancer patients, with the underlying mechanisms unclear. To decipher a specific impact of the liver microenvironment, we compared the effects of anti-PD-L1 antibody (αPD-L1) blockade on the same tumor grown s.c. or in the liver. APPROACH AND RESULTS: We generated s.c. tumors in mice by inoculating MC38 colorectal cancer (CRC) cells under the skin and metastatic liver tumors by portal vein or splenic injection of CRC cells. Tumor-bearing mice were treated by i.p. injection of αPD-L1, polyinosinic:polycytidylic acid (poly[I:C]), or both. αPD-L1 monotherapy significantly suppressed s.c. tumor growth, but showed no effect on metastatic liver tumors. However, the combination of αPD-L1 with poly(I:C), an innate immunity-stimulating reagent, robustly inhibited tumor progression in liver. The combination therapy effectively down-regulated myeloid-derived suppressor cells (MDSCs), but up-regulated ratios of M1/M2 macrophages, CD8/CD4, and CD8/regulatory T (Treg) cells infiltrated into liver tumors and whole liver. A group of long-lasting T-bet+ Eomes- PD-1- cytotoxic T cells was maintained in the combo-treated liver, leading to resistance to tumor recurrence. Depleting macrophages or blocking type Ⅰ interferon signaling abrogated the synergistic antitumor effect of αPD-L1 and poly(I:C), indicating a requirement of boosting innate immunity for optimized activation of cytotoxic T cells by PD-1/PD-L1 blockade. CONCLUSIONS: The poor response of liver cancers to αPD-L1 therapy is largely attributable to a unique hepatic immunotolerant microenvironment, independent of tumor origins or types. The success of a combinatorial immunotherapy relies on coordinated inhibition or activation of various innate and adaptive immune cell activities.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Xin B, Yang M, Wu P, et al. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology. 2022. PMID: 34860431. doi:10.1002/hep.32266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。